Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform
CARLSBAD, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,”…
Month: January 2023
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial
In a series of pre-clinical trials, Clearmind’s drug candidate MEAI significantly reduced body weight, improved…
SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
SciSparc and Clearmind’s collaboration continues to yield positive outcomes, the latest with Clearmind results for…
Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease
– Spin-off of technology platform to newly-formed Kimia Therapeutics intended to maximize the full potential…
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
Live video webcast on Wednesday, January 18th at 11:00 AM ET OCALA, Fla., Jan. 05,…
TCR² Therapeutics Announces Pipeline Priorities for 2023
gavo-cel Phase 2 clinical trial now focused on ovarian cancer cohort with first meaningful durability…
Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate
POSH-MAP and PORT-MAP investigator-sponsored trials to evaluate ability of ACER-801 (osanetant) to reduce hot flashes…
Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciences
Bellerophon to receive a license payment of $6 million, as well as royalties on net…
IMUNON Enters into Collaborative Research Agreement with The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform
LAWRENCEVILLE, NJ and PHILADELPHIA, PA, Jan. 05, 2023 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN),…
SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs
Andrew Elnatan Brings Nearly Three Decades of Global Regulatory Experience with Successful Breakthrough Therapy Designation…
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
— Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline…
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:…
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options NEW YORK, Jan….
INVECTYS, INC. TO PARTICIPATE IN THE 41st JP MORGAN HEALTHCARE CONFERENCE ON JANUARY 9-12, 2023
Houston, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) — Invectys, Inc. “Invectys”, a clinical-stage immunotherapy company…
Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology…
Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) — Reset Pharmaceuticals, Inc. (Reset Pharma), a privately…
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
– Final cohort of Phase 1 study projected to be complete in H1 2023 –…
World Orphan Drug Alliance Announces Agreement with Theratechnologies for the Distribution of EGRIFTA SV
Under the agreement, the World Orphan Drug Alliance (WODA) has obtained exclusive distribution rights to…
ORYZON to Give Updates on Corporate Progress in January
6th Sachs Annual Neuroscience Innovation Forum 12th Annual LifeSci Advisors Corporate Access Event 41st Annual…